Walleye Capital LLC Acquires 226,871 Shares of RxSight, Inc. $RXST

Posted by Francis Steltz on Jul 24th, 2026

Walleye Capital LLC raised its holdings in RxSight, Inc. (NASDAQ:RXST – Free Report) by 258.6% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 314,616 shares of the company’s stock after buying an additional 226,871 shares during the quarter. Walleye Capital LLC’s holdings in RxSight were worth $1,938,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its position in shares of RxSight by 6.3% in the first quarter. Bank of New York Mellon Corp now owns 100,306 shares of the company’s stock valued at $618,000 after acquiring an additional 5,978 shares during the period. Hsbc Holdings PLC acquired a new stake in shares of RxSight in the first quarter worth $473,000. Summit Securities Group LLC bought a new position in RxSight during the first quarter worth $30,000. Rockefeller Capital Management L.P. increased its position in RxSight by 27.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 23,848 shares of the company’s stock worth $248,000 after acquiring an additional 5,203 shares during the period. Finally, Corient Private Wealth LLC raised its stake in RxSight by 19.7% during the 4th quarter. Corient Private Wealth LLC now owns 36,095 shares of the company’s stock valued at $376,000 after purchasing an additional 5,933 shares during the last quarter. 78.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

RXST has been the subject of a number of research reports. Bank of America reduced their price target on shares of RxSight from $8.00 to $6.50 and set an “underperform” rating for the company in a report on Tuesday, July 7th. Wells Fargo & Company dropped their price objective on shares of RxSight from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Thursday, May 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of RxSight in a research report on Tuesday, July 7th. Jefferies Financial Group set a $6.50 target price on shares of RxSight in a research note on Tuesday, July 7th. Finally, Weiss Ratings downgraded RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, RxSight presently has a consensus rating of “Reduce” and a consensus price target of $8.89.

Get Our Latest Analysis on RXST

RxSight Trading Down 0.4%

Shares of NASDAQ RXST opened at $5.37 on Friday. The firm has a market capitalization of $222.32 million, a price-to-earnings ratio of -4.75 and a beta of 1.15. RxSight, Inc. has a one year low of $4.48 and a one year high of $13.22. The business has a fifty day simple moving average of $5.29 and a 200 day simple moving average of $6.91.

RxSight Company Profile

(Free Report)

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.